Rude Awakening Could Await China (China)
This article was originally published in PharmAsia News
China's lack of oversight concerning its pharmaceutical and food industries may lead to a global backlash against China as countries shy away from or even ban importation of Chinese medicines and food products. The United States on May 24 requested that China increase its oversight on food and drug export products. America and China currently are engaged in wide-ranging trade talks in which the United States is focusing on demanding China's currency be permitted to fluctuate more. The U.S. Food and Drug administration already has banned all U.S. imports of China-made toothpaste, after some Chinese toothpaste was found to contain an ingredient used in automotive antifreeze. Further problems in sensitive industries such as pharmaceuticals and food products may lead to trade embargo legislation against China from the U.S. Congress. Such incidents also would reverberate around the world, wounding China's food and pharmaceutical export companies. (Click here for more - May Require Free Registration
You may also be interested in...
Teligent has followed through with plans to condense its outstanding shares to raise their value and maintain a stock-exchange listing. Meanwhile, the company revealed a sizeable loss for the first quarter of this year, as it gave the latest on its warning letter-stricken facility in Buena, New Jersey.
Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.